What it's for (Indications)
- Indacaterol is a highly selective long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- This medication is designed to provide sustained bronchodilation, thereby reducing symptoms such as dyspnea, coughing, and wheezing, and improving exercise tolerance in these patients.
- It is crucial to emphasize that indacaterol is intended for maintenance therapy and is not indicated for the relief of acute bronchospasm.
- Its therapeutic role is as a cornerstone for daily management to prevent exacerbations and improve overall lung function and quality of life in individuals living with COPD.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for indacaterol (e.g., Onbrez Breezhaler) is the inhalation of the contents of one 75 mcg capsule once daily, using the provided Onbrez Breezhaler inhaler device. For certain regions or specific product formulations, doses of 150 mcg or 300 mcg once daily may be approved. It is critical that patients understand this medication is for once-daily administration at approximately the same time each day, and the dose should not exceed once daily. Higher doses do not provide additional benefit but may increase the risk of adverse effects. The capsule must not be swallowed; it is for inhalation only. Patients should be carefully instructed on the correct use of the inhaler device to ensure optimal drug delivery to the lungs and maximize therapeutic efficacy while minimizing potential systemic exposure. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects with indacaterol include nasopharyngitis, cough, upper respiratory tract infection, headache, muscle spasm, and peripheral edema.
- Less frequently, but of clinical significance, patients may experience tachycardia, palpitations, atrial fibrillation, tremor, dizziness, dry mouth, nausea, and dyspepsia.
- Due to its beta2-adrenergic agonist activity, indacaterol can also lead to metabolic effects such as hypokalemia and hyperglycemia, particularly in susceptible individuals.
- Serious but rare side effects include paradoxical bronchospasm, which can be life-threatening and requires immediate discontinuation of the drug and institution of alternative therapy.
- Patients should be advised to seek immediate medical attention if they experience sudden worsening of breathing or new-onset chest pain, unusual heartbeats, or severe allergic reactions such as angioedema.
Serious Warnings
- Black Box Warning: **WARNING: ASTHMA-RELATED DEATH** Long-acting beta2-adrenergic agonists (LABAs), such as indacaterol, increase the risk of asthma-related death. Indacaterol is explicitly **not indicated for the treatment of asthma**, and its safety and efficacy in patients with asthma have not been established. This serious risk has primarily been observed when LABAs are used as monotherapy for the treatment of asthma without concomitant inhaled corticosteroids. Therefore, indacaterol is contraindicated for the treatment of asthma without the concomitant use of an inhaled corticosteroid. Healthcare professionals must ensure that indacaterol is prescribed solely for its approved indication in chronic obstructive pulmonary disease (COPD) and that patients with asthma are not prescribed indacaterol as monotherapy. The potential for serious asthma-related adverse events underscores the critical importance of careful patient selection and adherence to approved indications.
- Indacaterol, as a long-acting beta2-adrenergic agonist (LABA), carries several important warnings.
- It should not be used for the relief of acute symptoms or for the treatment of acute exacerbations of COPD; patients should have a rescue inhaler available for such events.
- Paradoxical bronchospasm, a potentially life-threatening reaction, can occur; if it does, indacaterol should be discontinued immediately and alternative therapy instituted.
- Cardiovascular effects such as tachycardia, arrhythmias, and hypertension may occur, warranting caution in patients with pre-existing cardiovascular disorders.
- Indacaterol can also cause clinically significant hypokalemia and hyperglycemia, requiring careful monitoring in patients predisposed to these conditions.
- Caution is also advised in patients with convulsive disorders, thyrotoxicosis, or unusual responsiveness to sympathomimetic amines.
- Indacaterol is not indicated for the treatment of asthma.
How it Works (Mechanism of Action)
Indacaterol is a potent and highly selective long-acting beta2-adrenergic agonist (LABA). Its therapeutic action in chronic obstructive pulmonary disease (COPD) is primarily mediated through the stimulation of beta2-adrenergic receptors located on airway smooth muscle cells. Upon binding to these receptors, indacaterol activates adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Increased intracellular levels of cAMP lead to the activation of protein kinase A, which in turn phosphorylates various intracellular proteins. This cascade ultimately results in the relaxation of airway smooth muscle, leading to bronchodilation and improved airflow. The long duration of action of indacaterol (up to 24 hours) is attributed to its high lipophilicity and its sustained interaction with the beta2-receptor, allowing for once-daily dosing.
Commercial Brands (Alternatives)
No other brands found for this formula.